SciVision Biotech reports Sep revenue NT$61.1M
SciVision Biotech Inc. reported September revenue of NT$61,102,000 versus NT$60,337,000, and Jan–Sep revenue of NT$619,019,000 versus NT$635,232,000, per Taiwan Stock Exchange figures.
SciVision Biotech Inc. reported 2026 revenue of NT$61,102,000, up from NT$60,337,000 in 2025. For Jan-Sep, revenue was NT$619,019,000 versus NT$635,232,000 in 2025. Figures are in New Taiwan dollars.
Source: Taiwan Stock Exchange.